Award
National Institute of Allergy and Infectious Diseases 1R01AI193221-01
A multimodal approach for immunotherapy of Staphylococcus aureus bacteremia
Recipient
ABVACC, INC.
Award Amount
$638,953.00
Ceiling
$638,953.00
Awarded
August 22, 2025
Identifier
1R01AI193221-01
Development of an immunotherapy using monoclonal antibodies to combat Staphylococcus aureus infections, focusing on multiple bacterial targets and supported by preclinical and structural studies.
Description
This project aims to develop a novel immunotherapeutic antibody cocktail targeting multiple mechanisms of growth and immune evasion by Staphylococcus aureus, including pore-forming toxins, protein A, and autolysin, to protect against invasive diseases such as bacteremia and pneumonia.